Double-blind randomized controlled trial of isoxicam vs piroxicam in elderly patients with osteoarthritis of the hip and knee.

Abstract

1 Fifty-seven elderly patients with primary osteoarthritis of the hip and knee were entered into a double-blind, randomized, controlled parallel group trail to compare the efficacy and tolerability of isoxicam (maximum = 200 mg day-1) and piroxicam (maximum = 20 mg day-1). 2 Clinical assessments were made following a 1 week NSAID-free washout period and at biweekly intervals during the next 6 weeks of active treatment. 3 The majority of patients in both groups experienced a clinically important and statistically significant therapeutic response. 4 No statistically significant between-group differences were noted with respect to drug efficacy. 5 One patient was withdrawn from the piroxicam group because of lack of effect, but there were no such withdrawals from the isoxicam group. 6 Five patients were withdrawn from the piroxicam group because of adverse reactions compared to only one withdrawal from the isoxicam group. 7 This study indicates that isoxicam is an efficacious and well-tolerated once-daily NSAID for elderly patients with osteoarthritis.

• Authors: N Bellamy, W W Buchanan, E Grace
• Journal: British journal of clinical pharmacology (Br J Clin Pharmacol) Vol. 22 Suppl 2 Pg. 149S-155S ( 1986) ISSN: 0306-5251 [Print] England
• PMID: 3620274 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Anti-Inflammatory Agents, Non-Steroidal
• Piroxicam
• isoxicam

Topics

• Aged
• Aged, 80 and over
• Anti-Inflammatory Agents, Non-Steroidal (therapeutic use)
• Double-Blind Method
• Female
• Hip
• Humans
• Knee
• Male
• Middle Aged
• Osteoarthritis (drug therapy)
• Piroxicam (adverse effects, analogs & derivatives, therapeutic use)
• Random Allocation